SUTRO BIOPHARMA INC.

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

21 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract

20 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

10 Dec 2022 09:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

23 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones

08 Nov 2022 15:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition

03 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

02 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Departure of Chief Medical Officer

24 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference

01 Sep 2022 06:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones

08 Aug 2022 15:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference

03 Aug 2022 06:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck

26 Jul 2022 15:01:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs

12 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

27 Jun 2022 18:31:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jun 2022 15:01:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

02 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones

09 May 2022 15:30:00 By Nasdaq GlobeNewswire